Get the Stockscreener App
181.65
2.32%
-4.31
After Hours:
179.03
-2.62
-1.44%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Ligand Pharmaceuticals Inc stock is traded at $181.65, with a volume of 289.91K.
It is down -2.32% in the last 24 hours and down -12.17% over the past month.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
See More
Previous Close:
$185.96
Open:
$188.21
24h Volume:
289.91K
Relative Volume:
1.32
Market Cap:
$3.58B
Revenue:
$152.42M
Net Income/Loss:
$45.24M
P/E Ratio:
72.37
EPS:
2.51
Net Cash Flow:
$6.97M
1W Performance:
-5.24%
1M Performance:
-12.17%
6M Performance:
+18.97%
1Y Performance:
+63.08%
1-Day Range:
$180.24
$191.47
1-Week Range:
$179.20
$197.00
52-Week Range:
$93.58
$212.49
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Name
Ligand Pharmaceuticals Inc
Sector
Industry
Phone
858-550-7500
Address
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
181.65 | 3.66B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Citigroup | Buy |
| Apr-10-25 | Initiated | Stifel | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Resumed | Stephens | Overweight |
| Feb-04-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-06-20 | Initiated | Barclays | Overweight |
| Mar-24-20 | Downgrade | Argus | Buy → Hold |
| Mar-10-20 | Initiated | Guggenheim | Neutral |
| Feb-06-20 | Initiated | The Benchmark Company | Buy |
| Sep-19-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-03-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-06-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Oct-02-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-18 | Reiterated | Argus | Buy |
| Aug-17-18 | Initiated | Goldman | Neutral |
| Aug-08-18 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-21-18 | Initiated | Argus | Buy |
| Dec-27-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-17 | Resumed | H.C. Wainwright | Buy |
| Oct-05-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-16 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-11-16 | Initiated | Sidoti | Buy |
| Mar-03-16 | Initiated | H.C. Wainwright | Buy |
View All
Ligand Pharmaceuticals Inc Stock (LGND) Latest News
Ligand Pharmaceuticals Announces Fourth Quarter and Full Year 2025 Financial Results Call Scheduled for February 26, 2026 - Quiver Quantitative
Biopharma company Ligand to reveal 2025 results Feb. 26 - Stock Titan
Impax Asset Management Group plc Sells 60,000 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Is Ligand Pharmaceuticals Incorporated in a long term uptrendWeekly Trade Review & Expert Approved Trade Ideas - mfd.ru
Principal Financial Group Inc. Sells 7,210 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Trend Review: Is AMRN a cyclical or defensive stockQuarterly Trade Report & Safe Capital Investment Plans - baoquankhu1.vn
Ranger Investment Management L.P. Has $48.77 Million Stake in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), AbbVie (ABBV) and Bio-Techne (TECH) - The Globe and Mail
Ligand Pharmaceuticals (LGND) director sells $91k in stock By Investing.com - Investing.com India
Ligand Pharmaceuticals (LGND) director sells $91k in stock - Investing.com
Insider Sell: John Kozarich Sells Shares of Ligand Pharmaceutica - GuruFocus
Ligand Pharmaceuticals (LGND) Valuation Check As Partner Milestones Expand Royalty And Growth Potential - simplywall.st
Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Yahoo Finance
Ligand Pharmaceuticals (NASDAQ:LGND) Director John Kozarich Sells 467 Shares - MarketBeat
LGND: New Year Program Updates - Zacks Small Cap Research
Villere ST Denis J & Co. LLC Has $49.59 Million Stock Position in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
New York State Common Retirement Fund Decreases Stock Position in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Growth Value: Whats next for Global Business Travel Group Inc stockBuy Signal & Weekly High Potential Stock Alerts - baoquankhu1.vn
Earnings Update: Should you avoid IKNA stock right nowJuly 2025 Pullbacks & Technical Pattern Alert System - baoquankhu1.vn
Published on: 2026-02-02 03:00:22 - baoquankhu1.vn
Lisanti Capital Growth LLC Boosts Holdings in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Surprises Report: Can TZOO weather a recessionIndex Update & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Acuitas Investments LLC Purchases 382,597 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Whale Trades: What is the dividend yield of Ligand Pharmaceuticals IncorporatedJuly 2025 Pullbacks & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Can Ligand Pharmaceuticals Incorporated outperform in the next rallyWeekly Stock Report & Entry Point Confirmation Signals - mfd.ru
Breakout Watch: Whats the profit margin of Ligand Pharmaceuticals IncorporatedMarket Rally & AI Driven Stock Movement Reports - baoquankhu1.vn
7,200 Shares in Ligand Pharmaceuticals Incorporated $LGND Acquired by Pier 88 Investment Partners LLC - MarketBeat
Is Ligand Pharmaceuticals Incorporated in a bullish channelBull Run & AI Enhanced Execution Alerts - mfd.ru
Aug Opening: Can KRUS benefit from deglobalizationJuly 2025 Summary & Low Risk Growth Stock Ideas - baoquankhu1.vn
Pullback Watch: Is Ligand Pharmaceuticals Incorporated a stock for growth or value investors2025 Pullback Review & Capital Efficiency Focused Ideas - baoquankhu1.vn
Massachusetts Financial Services Co. MA Buys 202,103 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Stephens Investment Management Group LLC Sells 50,271 Shares of Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
SG Americas Securities LLC Has $2.08 Million Stock Position in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Could Be 37% Below Their Intrinsic Value Estimate - Yahoo Finance UK
Travere, Ligand Hammered On A Surprise Delay For Their Linchpin Drug - Investor's Business Daily
Ligand Pharmaceuticals stock slides as FDA pushes back Travere’s Filspari decision to April 13 - TechStock²
Ligand Pharmaceuticals (NASDAQ:LGND) Shares Gap DownShould You Sell? - MarketBeat
Patterns Watch: Can Ligand Pharmaceuticals Incorporated stock continue upward trendJuly 2025 Breakouts & Safe Capital Growth Plans - Bộ Nội Vụ
Published on: 2026-01-13 22:28:13 - Bộ Nội Vụ
Gamble on Huge Gains with These 3 Best Biotech Stocks to Buy for 2026 - Yahoo Finance
Can Ligand Pharmaceuticals Incorporated stock rebound after recent weaknessJuly 2025 Fed Impact & Safe Entry Zone Tips - Улправда
Will Ligand Pharmaceuticals Incorporated stock remain a Wall Street favoriteTrade Risk Assessment & Daily Risk Controlled Trade Plans - Улправда
What technical signals suggest for Ligand Pharmaceuticals Incorporated stockJuly 2025 EndofMonth & High Win Rate Trade Tips - Улправда
Is Ligand Pharmaceuticals Incorporated stock attractive for hedge fundsQuarterly Trade Report & Entry Point Confirmation Signals - ulpravda.ru
Is Ligand Pharmaceuticals Incorporated stock a top momentum playExit Point & Free Long-Term Investment Growth Plans - Улправда
Is Ligand Pharmaceuticals Incorporated (LGDN) stock positioned for digital growth eraMarket Performance Summary & Weekly High Return Opportunities - Улправда
Is Ligand Pharmaceuticals Incorporated stock positioned well for digital economyJuly 2025 Snapshot & Weekly Setup with High ROI Potential - Улправда
Risk Recap: How Ligand Pharmaceuticals Incorporated stock reacts to oil pricesMarket Trend Review & Verified Stock Trade Ideas - Улправда
Ligand Pharmaceuticals director Kozarich sells $88,532 in stock By Investing.com - Investing.com South Africa
Book value per share of Ligand Pharmaceuticals Incorporated – OTC:LGNYZ - TradingView — Track All Markets
Ligand Pharmaceuticals Inc Stock (LGND) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):